Bcr-Abl inhibition as a modality of CML therapeutics

Elisabeth Buchdunger, Alex Matter, Brian J. Druker

Research output: Contribution to journal › Review article › peer-review

101 Scopus citations

Fingerprint

Dive into the research topics of 'Bcr-Abl inhibition as a modality of CML therapeutics'. Together they form a unique fingerprint.